Baicalein, a novel apoptotic agent for hepatoma cell lines: A potential medicine for hepatoma

被引：54

作者：

Chen, CH

Huang, LLH

Huang, CC

Lin, CC

Lee, Y

Lu, FJ ^{[1
]}

机构：

[1] Natl Taiwan Univ, Coll Med, Dept Biochem, Taipei, Taiwan

[2] Natl Cheng Kung Univ, Inst Biotechnol, Tainan 70101, Taiwan

[3] Chang Gung Mem Hosp, Dept Pathol, Kaohsiung, Taiwan

[4] Kaohsiung Med Univ, Sch Pharm, Kaohsiung, Taiwan

来源：

NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL | 2000年 / 38卷 / 02期

关键词：

D O I：

10.1207/S15327914NC382_19

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This study has demonstrated that baicalein has anticancer effectiveness against human hepatoma cells. The dose response of baicalein in Hep G2 and Hep J2 cells indicates that baicalein decreased viability > 90%. In comparison, baicalein had only minimal effects on the viability of control Chang liver cells. Flow cytometric analysis showed that baicalein inhibited the cell cycle of Hep G2 cells in the S phase. In addition, baicalein treatment resulted in a decreased mitochondrial transmembrane potential and damaged the integrity of the cell membrane. The TdT-mediated dUTP-biotin nick end labeling assay results indicated that baicalein elicited a significant increase of DNA fragmentation in Hep G2 cells after incubation for 48 hours. These results indicate that baicalein is an effective antihepatoma agent with minimal influence on noncancer cells. The effects of baicalein on Hep G2 cells include inhibition of the S phase of the cell cycle, dysfunction of mitochondria, and initiation of apoptosis.

引用

页码：287 / 295

页数：9

共 34 条

[1] Skin cancer chemopreventive effects of a flavonoid antioxidant silymarin are mediated via impairment of receptor tyrosine kinase signaling and perturbation in cell cycle progression [J].